With generic competition in Europe looming on the horizon, industry powerhouse Amgen Inc. once again reported strong earnings, thanks largely to the company's erythropoietin (EPO) franchise. (BioWorld Today)

It was déja vu, but not the same. In August 2002, when ViroPharma Inc.'s deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) for the common cold ended - the arrangement was terminated by mutual consent, and ViroPharma's stock fell more than 25 percent - CEO Michel de Rosen told investors: "Today is the day when we begin to look forward again." (BioWorld Financial Watch)